Search results for "Retinal Neovascularization"

showing 10 items of 11 documents

DNA methylomes reveal biological networks involved in human eye development, functions and associated disorders

2017

This work provides a comprehensive CpG methylation landscape of the different layers of the human eye that unveils the gene networks associated with their biological functions and how these are disrupted in common visual disorders. Herein, we firstly determined the role of CpG methylation in the regulation of ocular tissue-specification and described hypermethylation of retinal transcription factors (i.e., PAX6, RAX, SIX6) in a tissue-dependent manner. Second, we have characterized the DNA methylome of visual disorders linked to internal and external environmental factors. Main conclusions allow certifying that crucial pathways related to Wnt-MAPK signaling pathways or neuroinflammation are…

0301 basic medicineMaleADNlcsh:MedicineUllRetinal NeovascularizationEyeEpigenesis Genetic0302 clinical medicinelcsh:ScienceChildCàncerCancerRegulation of gene expressionMultidisciplinaryRetinoblastomaMelanomaMethylationDNA NeoplasmOphthalmopathiesNeoplasm ProteinsGene Expression Regulation NeoplasticOftalmologiaChild PreschoolDNA methylationFemaleMetilacióOftalmopatiesAdultMAP Kinase Signaling SystemBiologyMethylationArticle03 medical and health sciencesETS1medicineHumansEye ProteinsTranscription factorDiabetic RetinopathyEye Neoplasmslcsh:RDNADNA Methylationmedicine.diseaseeye diseasesOphthalmology030104 developmental biologyImmunology030221 ophthalmology & optometryCancer researchlcsh:QPAX6
researchProduct

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of …

2018

PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corr…

Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Intravitreal ranibizumab treatment of retinal angiomatous proliferation

2010

. Purpose:  To determine the efficacy of intravitreal injections of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration. Methods:  Retrospective, consecutive case series of 26 eyes (26 patients) treated with intravitreal injections of 0.5 mg ranibizumab for RAP. Patients received intravitreal injections at monthly intervals during upload phase for a 3-month period. Results:  Mean visual acuity before treatment was 0.75 ± 0.38logMAR (mean ± SD, n = 26). In the upload phase, mean visual acuity improved 4 weeks after the initial injection to 0.6 ± 0.37logMAR (n = 26) and to 0.53 ± 0.34logMAR (n = 26) 4 weeks after the third mo…

MaleAngiomatosismedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsFoveal thicknessRetinal NeovascularizationAntibodies Monoclonal Humanizedchemistry.chemical_compoundOpticsRanibizumabOphthalmologymedicineHumansMaintenance phaseAgedRetrospective StudiesAged 80 and overbusiness.industryRetinalGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseeye diseasesOphthalmologyTreatment OutcomechemistryIntravitreal InjectionsRetreatmentWet Macular DegenerationFemalesense organsRanibizumabIntravitreal ranibizumabmedicine.symptombusinessTomography Optical Coherencemedicine.drugActa Ophthalmologica
researchProduct

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity…

2021

Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07…

MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studies
researchProduct

Subretinal neovascularization in anterior ischemic optic neuropathy.

1991

A 66-year-old man with typical anterior ischemic optic neuropathy in one eye suffered from edema of the optic disc without functional changes in the fellow eye. However, 7 months later, a reduction in visual acuity, a change in the visual field and a worsening of the contrast-sensitivity curve demonstrated the development of typical anterior ischemic optic neuropathy in this eye as well. After another 6-month period, in addition to these changes, an extensive subretinal neovascular membrane developed in the papillomacular area, which further reduced the patient's visual acuity and required treatment with laser photocoagulation. To our knowledge, this is the first case report of the occurren…

Malemedicine.medical_specialtyVisual acuitygenetic structuresFundus OculiEye diseaseVisual AcuityLight CoagulationRetinal NeovascularizationContrast SensitivityCellular and Molecular NeuroscienceIschemiamedicineHumansFluorescein AngiographyAgedRetinabusiness.industryOptic Nervemedicine.diseaseeye diseasesSensory SystemsVisual fieldSurgeryOphthalmologymedicine.anatomical_structureOptic nerveAnterior ischemic optic neuropathysense organsmedicine.symptomVisual FieldsbusinessOptic discRetinopathyPapilledemaGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Involvement of plasmalogens in post-natal retinal vascular development

2014

Objective: Proper development of retinal blood vessels is essential to ensure sufficient oxygen and nutrient supplies to the retina. It was shown that polyunsaturated fatty acids (PUFAs) could modulate factors involved in tissue vascularization. A congenital deficiency in ether-phospholipids, also termed "plasmalogens'', was shown to lead to abnormal ocular vascularization. Because plasmalogens are considered to be reservoirs of PUFAs, we wished to improve our understanding of the mechanisms by which plasmalogens regulate retinal vascular development and whether the release of PUFAs by calcium-independent phospholipase A2 (iPLA2) could be involved. [br/] Methods and Results: By characterizi…

MaleretinaOrganes des sensAngiogenesis[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionlcsh:MedicineRetinal NeovascularizationBiochemistryImmunoenzyme TechniquesMicechemistry.chemical_compoundangiogenesisMedicine and Health Sciencesangiogenesis;astrocytes;capillaries;endothelial cells;gene expression;phospholipids;retina;retinal vesselscapillarieslcsh:ScienceCells CulturedOligonucleotide Array Sequence AnalysisMice KnockoutMultidisciplinarymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionLipidsendothelial cellsCell biologyEndothelial stem cellmedicine.anatomical_structureBiochemistry[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansAlimentation et NutritionFatty Acids UnsaturatedRetinal DisordersFemaleResearch ArticleAstrocyteEndotheliumSensory OrgansPlasmalogensBiologyReal-Time Polymerase Chain ReactionGroup VI Phospholipases A2AngiopoietinElectroretinographymedicineFood and NutritionAnimalsRNA Messenger[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansphospholipidsRetinaGene Expression Profilinglcsh:Rretinal vesselsastrocytesBiology and Life SciencesRetinalMice Inbred C57BLOphthalmologyAnimals Newbornchemistrygene expressionlcsh:QEndothelium Vascular[SDV.AEN]Life Sciences [q-bio]/Food and NutritionAcyltransferasesBiomarkersDevelopmental BiologyElectroretinography
researchProduct

Norrie gene product is necessary for regression of hyaloid vessels.

2004

To investigate the nature and origin of the vitreous membranes in mice with knock-out of the Norrie gene product (ND mice).Eighty-two eyes of ND mice of different age groups (postnatal day [P]0-13 months) and 95 age-matched wild-type control mice were investigated. In vitreoretinal wholemounts and in sagittal sections, vessels and free cells were visualized by labeling for lectin. In addition, staining with a marker for macrophages (F4/80) and collagen XVIII/endostatin known to be involved in regression of hyaloid vessels was performed for light and electron microscopic investigations. Endostatin expression was confirmed by Western blot analysis.Wild-type controls showed the typical pattern…

Pathologymedicine.medical_specialtygenetic structuresAngiogenesisBlotting WesternNerve Tissue ProteinsBiologyRetinal NeovascularizationBlindnessGene productchemistry.chemical_compoundMiceVasculogenesismedicineAnimalsEye AbnormalitiesEye ProteinsMicroscopy ImmunoelectronMice KnockoutMembranesRetinal DegenerationRetinal VesselsRetinalGenetic Diseases X-LinkedAnatomyAntigens Differentiationeye diseasesEndostatinsVitreous Bodymedicine.anatomical_structurechemistryCirculatory systemcardiovascular systemsense organsEndostatinBlood vesselInvestigative ophthalmologyvisual science
researchProduct

Visual Health Nanocomposites: Present and Future

2021

Background: In recent years, the therapeutics for eye diseases as retinopathy diabetic, dry eye, glaucoma and contact lenses fabrication are including nanocompounds as ocular drug delivery systems, biomarkers for detection of eye diseases, copper and silver ions that has been incorporated by means of the nanotechnology for the production of less toxic and more effective alternatives. Several compounds such as silver nanoparticles, turmeric-based nanocomposites, neovascularization blockers and nanoparticles extracted from the plant Costus pictus among others have been researched for this purpose. Those compounds are some of the promising research efforts that are studying and will contribute…

genetic structuresBlindnessbusiness.industryGlaucomamedicine.diseaseBioinformaticseye diseasesSilver nanoparticleOphthalmic drugsRetinal neovascularizationCostus pictusmedicinesense organsbusinessRetinopathy
researchProduct

Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or comb…

2021

Purpose Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non-interventional follow-up, performed to evaluate long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR. Methods Seventy-three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow-up …

medicine.medical_specialtyVisual acuityCombination therapyVisual AcuityAngiogenesis InhibitorsLight CoagulationPanretinal laser photocoagulation03 medical and health sciencesRetinal neovascularization0302 clinical medicineOphthalmologyRanibizumabMedicineHumansDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseCombined Modality TherapyDiscontinuationOphthalmologyIntravitreal Injections030221 ophthalmology & optometryObservational studyRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesActa ophthalmologicaReferences
researchProduct

Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic re…

2019

Purpose Panretinal photocoagulation (PRP) is the current standard of care in proliferative diabetic retinopathy (PDR). However, treatment with anti-vascular endothelial growth factor agents might offer better patient outcomes with fewer side-effects. The PRIDE study aimed to assess the efficacy and safety of ranibizumab with or without PRP compared with PRP alone in patients with PDR. Methods A total of 106 PDR patients without diabetic macular oedema were randomized to receive ranibizumab 0.5 mg monotherapy (n = 35), PRP (n = 35) or combined ranibizumab 0.5 mg/PRP (n = 36). The primary objective of this 12-month, multicentre, phase II study was to investigate the change in area of retinal …

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industrySignificant differencePhases of clinical researchGeneral MedicineDiabetic retinopathyPanretinal laser photocoagulationmedicine.diseaseAlternative treatment03 medical and health sciencesOphthalmologyRetinal neovascularization0302 clinical medicineOphthalmology030221 ophthalmology & optometrymedicineRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugActa Ophthalmologica
researchProduct